NASDAQ: BFRIBiofrontera Inc Stock
$0.80-0.04 (-4.76%)
Updated Apr 23, 2025
BFRI Price
$0.80
Fair Value Price
-$0.24
Market Cap
$7.05M
52 Week Low
$0.65
52 Week High
$2.22
P/E
-0.25x
P/B
1.59x
P/S
0.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$37.32M
Earnings
-$17.76M
Gross Margin
50.1%
Operating Margin
-42.07%
Profit Margin
-47.6%
Debt to Equity
3.99
Operating Cash Flow
-$10M
Beta
0.91
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BFRI Overview
Biofrontera Inc. is a biopharmaceutical company focused on the treatment of dermatological conditions. The company offers Ameluz, a prescription drug approved for use in combination with the company's licensor's medical device. Its RhodoLED lamp series is used to provide photodynamic treatment of mild-to-moderate actinic keratosis of the face and scalp. Biofrontera also provides Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 1997 and is headquartered in Woburn, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BFRI's potential to beat the market
- BFRI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BFRI
RankedUnranked of 56
RankedUnranked of 56
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.30 | A | |
| $30.84 | A | |
| $25.20 | A |
Be the first to know about important BFRI news, forecast changes, insider trades & much more!
BFRI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BFRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BFRI ($0.80) is overvalued by 429.54% relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BFRI ($0.80) is not significantly undervalued (429.54%) relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BFRI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BFRI due diligence checks available for Premium users.
Valuation
BFRI fair value
Fair Value of BFRI stock based on Discounted Cash Flow (DCF)
Price
$0.80
Fair Value
-$0.24
Undervalued by
431.62%
BFRI ($0.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BFRI ($0.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BFRI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BFRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.25x
Industry
20.92x
Market
26.95x
BFRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.59x
Industry
2.03x
BFRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BFRI's financial health
Profit margin
Revenue
$12.6M
Net Income
-$1.4M
Profit Margin
-11.1%
BFRI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BFRI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.1M
Liabilities
$17.7M
Debt to equity
3.99
BFRI's short-term assets ($20.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BFRI's short-term assets ($20.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BFRI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BFRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.0M
Investing
-$1.0k
Financing
$4.1M
BFRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BFRI vs Pharmaceutical Stocks
Biofrontera Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.